Abstract：Objective To investigate the treatment outcomes and influencing factors among elderly patients with pulmonary tuberculosis in Lishui City, Zhejiang Province, so as to provide a basis for optimizing the prevention and control strategies of pulmonary tuberculosis and reducing the risk of adverse treatment outcomes among elderly patients. Methods Data on patients aged ≥60 years with pulmonary tuberculosis in Lishui City from 2016 to 2022 were collected from the Tuberculosis Information Management System of the China Disease Prevention and Control Information System, including basic information, diagnosis and treatment details, and laboratory test results. The successful treatment rate and the incidence of adverse treatment outcomes were calculated. Factors affecting adverse treatment outcomes among elderly patients with pulmonary tuberculosis were analyzed using multivariable logistic regression model. Results A total of 3 094 elderly patients with pulmonary tuberculosis were registered in Lishui City from 2016 to 2022, with a median age of 70 (interquartile range, 13) years. There were 2 396 male patients (77.44%) and 698 female patients (22.56%). A total of 2 676 patients achieved successful treatment, with a successful treatment rate of 86.49%. The successful treatment rate demonstrated a significant upward trend from 2016 to 2022 (P<0.05). There were 418 patients with adverse treatment outcomes, accounting for an incidence of 13.51%. The main types of adverse outcomes were death and loss to follow-up, with 199 and 100 patients, accounting for 47.61% and 23.92%, respectively. Multivariable logistic regression analysis showed that elderly patients with pulmonary tuberculosis who were male (OR=1.333, 95%CI: 1.018-1.745), aged ≥70 years (70-<80 years, OR=1.909, 95%CI: 1.469-2.481; ≥80 years, OR=3.878, 95%CI: 2.967-5.068), living in rural areas (OR=1.332, 95%CI: 1.068-1.661), with positive etiological results (OR=1.470, 95%CI: 1.143-1.889), and undergoing retreatment (OR=1.923, 95%CI: 1.419-2.607) had a higher risk of adverse treatment outcomes. Conclusions The successful treatment rate showed an upward trend among elderly patients with pulmonary tuberculosis in Lishui City from 2016 to 2022. Gender, age, place of residence, etiological results, and treatment type were influencing factors for adverse treatment outcomes among elderly patients with pulmonary tuberculosis.
[1] 吴倩,张钰,刘魁,等.2016—2020年浙江省肺结核流行特征分析[J].预防医学,2022,34(5):487-491. WU Q,ZHANG Y,LIU K,et al.Epidemiological characteristics of pulmonary tuberculosis in Zhejiang Province from 2016 to 2020[J].China Prev Med J,2022,34(5):487-491.(in Chinese) [2] GARDNER TOREN K,SPITTERS C,PECHA M,et al.Tuberculosis in older adults:Seattle and King County,Washington[J].Clin Infect Dis,2020,70(6):1202-1207. [3] SHARMA M,ONOZAKI I,NUNN P.TB in older people in Asia:why it is important[J].Int J Tuberc Lung Dis,2021,25(7):521-524. [4] 陈可,李锦成,虞浩,等.扬州市65岁及以上老年人群肺结核流行特征分析[J].预防医学,2023,35(10):877-880. CHEN K,LI J C,YU H,et al.Epidemiological characteristics of pulmonary tuberculosis among the elderly population at ages of 65 years and older in Yangzhou City[J].China Prev Med J,2023,35(10):877-880.(in Chinese) [5] 中华人民共和国卫生部.肺结核诊断标准:WS 288—2008[S].北京:人民卫生出版社,2008. Ministry of Health of the People's Republic of China.Diagnostic criteria for pulmonary tuberculosis:WS 288—2008[S].Beijing:People's Medical Publishing House,2008.(in Chinese) [6] 中华人民共和国卫生部.结核病分类:WS 196—2001[S].北京:中国标准出版社,2002. Ministry of Health of the People's Republic of China.Classification of tuberculosis:WS 196—2001[S].Beijing:Standards Press of China,2002.(in Chinese) [7] 中华人民共和国国家卫生和计划生育委员会.肺结核诊断:WS 288—2017[S].北京:中国标准出版社,2018. National Health and Family Planning Commission of the People's Republic of China.Diagnosis for pulmonary tuberculosis:WS 288—2017[S].Beijing:Standards Press of China,2018.(in Chinese) [8] 中华人民共和国国家卫生和计划生育委员会.结核病分类:WS 196—2017[S].北京:中国标准出版社,2018. National Health and Family Planning Commission of the People's Republic of China.Classification of tuberculosis:WS 196—2017[S].Beijing:Standards Press of China,2018.(in Chinese) [9] 中国疾病预防控制中心结核病控制中心.中国结核病防治规划实施工作指南(2008年版)[EB/OL][2025-08-07].https://tb.chinacdc.cn/zcfg/sszn/201207/t20120711_64166.htm. [10] 赵雁林,陈明亭.中国结核病防治工作技术指南[Z].北京:人民卫生出版社,2021. ZHAO Y L,CHEN M T.Technical guide for tuberculosis prevention and control in China[Z].Beijing:People's Medical Publishing House,2021.(in Chinese) [11] 杨超,王晶,杨朝辉,等.2016—2022年北京市通州区60岁及以上老年人群肺结核流行特征及治疗转归分析[J].中国防痨杂志,2024,46(4):403-410. YANG C,WANG J,YANG Z H,et al.Analysis of the epidemiological characteristics and treatment outcomes of pulmonary tuberculosis aged ≥60 years old in Tongzhou District of Beijing,2016-2022[J].Chin J Antituberc,2024,46(4):403-410.(in Chinese) [12] 张亚敬,姜影,孙浩,等.154例老年肺结核患者的发现与治疗转归情况分析[J].结核与肺部疾病杂志,2023,4(1):48-53. ZHANG Y J,JIANG Y,SUN H,et al.Analysis of detection and treatment prognosis of 154 elderly pulmonary tuberculosis patients[J].J Tuberc Lung Dis,2023,4(1):48-53.(in Chinese) [13] 马玉宝,王铂,何钰珏.2018—2022年甘肃省≥60岁老年肺结核患者治疗转归情况及影响因素分析[J].疾病监测,2025,40(2):184-188. MA Y B,WANG B,HE Y J.Analysis on treatment outcomes and influencing factors in pulmonary tuberculosis patients aged ≥60 years in Gansu,2018-2022[J].Dis Surveill,2025,40(2):184-188.(in Chinese) [14] 段晓菲,吴桂辉,杨洁,等.2012—2022年成都市肺结核流行特征与治疗转归分析[J].新发传染病电子杂志,2024,9(5):19-24. DUAN X F,WU G H,YANG J,et al.Analysis on epidemic characteristics and treatment effect of pulmonary tuberculosis in Chengdu from 2012 to 2022[J].Electron J Emerg Infect Dis,2024,9(5):19-24.(in Chinese) [15] 谢祎,韩晶,于维莉,等.天津市肺结核患者短程督导治疗期抗结核治疗效果及死亡影响因素分析[J].中国公共卫生,2020,36(1):126-129. XIE Y,HAN J,YU W L,et al.Treatment effect and risk factors of mortality among pulmonary tuberculosis patients with directly observed treatment short-course in Tianjin city[J].Chin J Public Health,2020,36(1):126-129.(in Chinese) [16] 杨洁莹,肖新才,杜雨华,等.2014—2023年广州市肺结核并发糖尿病患者流行特征及治疗转归分析[J].中国防痨杂志,2024,46(12):1504-1510. YANG J Y,XIAO X C,DU Y H,et al.Analysis of epidemiological characteristics and therapeutic prognosis among pulmonary tuberculosis patients complicated with diabetes mellitus in Guangzhou City from 2014 to 2023[J].Chin J Antituberc,2024,46(12):1504-1510.(in Chinese) [17] 陈丽燕,张晓强,余建平,等.2013—2022年杭州市临平区登记肺结核患者特点及治疗转归影响因素分析[J].中国防痨杂志,2024,46(12):1459-1468. CHEN L Y,ZHANG X Q,YU J P,et al.Analysis of characteristics and factors influencing treatment outcome of registered tuberculosis patients in Linping District,Hangzhou City from 2013 to 2022[J].Chin J Antituberc,2024,46(12):1459-1468.(in Chinese) [18] TIWARI S,KUMAR A,KAPOOR S K.Relationship between sputum smear grading and smear conversion rate and treatment outcome in the patients of pulmonary tuberculosis undergoing dots:a prospective cohort study[J].Indian J Tuberc,2012,59(3):135-140. [19] 吴玉姣,左小明,秦科宇,等.常州市老年肺结核患者利福平耐药分析[J].预防医学,2024,36(2):162-164,168. WU Y J,ZUO X M,QIN K Y,et al.Rifampicin resistance among elderly patients with pulmonary tuberculosis in Changzhou City[J].China Prev Med J,2024,36(2):162-164,168.(in Chinese) [20] 高磊,梁雅雪,刘盛盛,等.144例老年利福平耐药肺结核患者治疗转归及影响因素分析[J].中国防痨杂志,2024,46(7):799-807. GAO L,LIANG Y X,LIU S S,et al.Analysis of treatment outcomes and influencing factors in 144 elderly patients with rifampicin drug-resistant pulmonary tuberculosis[J].Chin J Antituberc,2024,46(7):799-807.(in Chinese) [21] 唐小芬,秦道新,金凤霞,等.2012—2022年罗湖区肺结核患者利福平和异烟肼耐药分析[J].预防医学,2024,36(6):536-539. TANG X F,QIN D X,JIN F X,et al.Rifampicin and isoniazid resistance among pulmonary tuberculosis patients in Luohu District from 2012 to 2022[J].China Prev Med J,2024,36(6):536-539.(in Chinese)
